A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This is a prospective, open, phase I clinical study to evaluate the safety and tolerability
of a CDK4 / 6 inhibitor and a MEK inhibitor in the treatment of metastatic digestive system
tumors